Dmitry Balyasny’s Crescent Biopharma CBIO Stock Holding History

Dmitry Balyasny’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.9M	Buy	1,662,917 +152,884	+10%	+$2.98M	0.04%	547
2026 Q1	$27.7M	Buy	1,510,033 +1,398,318	+1,252%	+$16.1M	0.04%	558
2025 Q4	$1.32M	Buy	+111,715	New	+$1.42M	﹤0.01%	2060
2025 Q2	–	Sell	-3,826	Closed	-$80.3K	–	3015
2025 Q1	$80.3K	Buy	+3,826	New	+$102K	﹤0.01%	2694
2024 Q2	–	Sell	-406	Closed	-$42.2K	–	2765
2024 Q1	$122K	Buy	+406	New	+$121K	﹤0.01%	2482
2018 Q2	–	Sell	-1,020	Closed	-$1.66M	–	1903
2018 Q1	$1.66M	Buy	+1,020	New	+$2.12M	0.01%	1048

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dmitry Balyasny's CBIO Position: Q2 2026 in Review

Dmitry Balyasny increased its Crescent Biopharma (CBIO) stake by 10% in Q2 2026, buying an estimated $2.98M and bringing the position to 1,662,917 shares worth $29.9M. The position accounts for 0.04% of the portfolio, ranked #547.

Dmitry Balyasny first reported a position in CBIO in Q1 2018 and has held it in 6 quarters since. 81 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Dmitry Balyasny held 1,662,917 shares of Crescent Biopharma worth $29.9M as of Q2 2026.
Dmitry Balyasny bought 152,884 Crescent Biopharma shares in Q2 2026, an estimated $2.98M.
Crescent Biopharma made up 0.04% of Dmitry Balyasny's portfolio in Q2 2026, its #547 holding.
Dmitry Balyasny first reported a position in Crescent Biopharma in Q1 2018 and has held it in 6 quarters since.
81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.